Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,323 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Targeted agent Clear all

Conditions: Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions: Lonapegsomatropin, Placebo, Somatropin; Drug · Other
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 23 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Darbepoetin alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 42
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more

Conditions: Substance Use Disorders
Interventions: Standard Contingency Management (CM), Enhanced Contingency Management (CM+); Behavioral
Lead sponsor: Oregon Social Learning Center; Other
Eligibility: 12 Years to 18 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions: Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care; Behavioral · Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Pain, Headache, Musculoskeletal Pain
Interventions: Usual Care/Guideline, Opioid Justification, Provider Comparison; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 22,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography; Procedure · Drug · Dietary Supplement
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 1,980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 24
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more

Conditions: Cystic Fibrosis
Interventions: Nutropin AQ; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Alzheimer Disease
Interventions: Dasatinib + Quercetin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 65 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type2 Diabetes
Interventions: Afrezza Inhalant Product; Drug
Lead sponsor: Model Clinical Research LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Leukemia, Myelodysplasia
Interventions: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Year to 65 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 28
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 22 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Glargine Injection, Lantus®; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more

Conditions: Relapsed/Refractory Ovarian Carcinoma
Interventions: NTB-928; Drug
Lead sponsor: TeneoSeven, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more

Conditions: Pain
Interventions: Moderate Procedural Sedation with a sedative medication., Deep Procedural Sedation with a sedative medication., propofol; Procedure · Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Persistent Spinal Pain Syndrome
Interventions: Pain pump, Bupivacain 0.625%/Fentanyl 2mcg/ml, Spinal Cord Stimulator (SCS); Device · Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Thymoma, Thymus Neoplasms
Interventions: Sunitinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Cancer
Interventions: sorafenib tosylate; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Cleveland, Ohio • Dallas, Texas

Conditions: Coronary Heart Disease, Myocardial Infarction
Interventions: Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation; Other · Behavioral
Lead sponsor: Middle Tennessee Research Institute; Other
Eligibility: 60 Years to 90 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Emavusertib, Venetoclax; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 12
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Alcohol or Other Drugs Use
Interventions: HealthCall+Motivational Interviewing, Motivational Interviewing; Behavioral
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Ventricular Premature Beats, Contractions, or Systoles, Cardiomyopathies
Interventions: Radiofrequency ablation, Amiodarone (Antiarrhythmic drug); Procedure · Drug
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more

Conditions: Acute Kidney Injury
Interventions: Medication reconciliation, Blood Pressure Management; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Birmingham, Alabama • Lexington, Kentucky • Nashville, Tennessee

Conditions: Acute Lymphocytic Leukemia, Lymphoma
Interventions: Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Angina Pectoris, Microvascular Angina, Vasospastic Angina, Myocardial Bridge of Coronary Artery
Interventions: Amlodipine, Nebivolol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Enhancing Adolescent Substance Abuse Treatment

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Growth Hormone Therapy for Wasting in Cystic Fibrosis

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Study of NTB-928 in R/R OC

Moderate Versus Deep Procedural Sedation With Propofol in the Emergency Department

Patient Preference and Long-term Outcomes in Persistent Spinal Pain Syndrome: A Prospective Study Comparing Spinal Cord Stimulation to Intrathecal Drug Delivery.

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab

Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

HealthCall-S: A Pilot Study Targeting Concurrent Non-injection Drug Use and Alcohol in HIV Primary Care Clinics

Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)

Maximizing Acute Kidney Injury End-point Intervention Post-Discharge (MAKE-IT) Study

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries